Technical Analysis for RARE - Ultragenyx Pharmaceutical Inc.

Grade Last Price % Change Price Change
grade B 66.04 -0.18% -0.12
RARE closed down 0.18 percent on Wednesday, October 17, 2018, on approximately normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. It was able to bounce off of its 200 day moving average, an important long-term support line. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Earnings due: Nov 1

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Flat Down Down
See historical RARE trend table...

Date Alert Name Type % Chg
Oct 17 200 DMA Support Bullish 0.00%
Oct 17 NR7 Range Contraction 0.00%
Oct 17 Inside Day Range Contraction 0.00%
Oct 17 Wide Bands Range Expansion 0.00%
Oct 17 Oversold Stochastic Weakness 0.00%
Oct 16 Slingshot Bearish Bearish Swing Setup -0.18%
Oct 16 Crossed Above 200 DMA Bullish -0.18%
Oct 16 Lower Bollinger Band Walk Weakness -0.18%
Oct 16 Wide Bands Range Expansion -0.18%
Oct 16 Oversold Stochastic Weakness -0.18%

Older signals for RARE ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Ultragenyx Pharmaceutical Inc., a development-stage biotechnology company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare diseases in the United States. It develops various biologics product candidates, including KRN23, a human monoclonal antibody to bind and reduce the biological activity of fibroblast growth factor to enhance abnormally low phosphate levels in patients with X-linked hypophosphatemia; recombinant human beta-glucuronidase, an intravenous enzyme replacement therapy for the treatment of mucopolysaccharidosis 7; and recombinant human protective protein cathepsin-A, an enzyme replacement therapy for galactosialidosis. The company is also developing a range of small-molecule product candidates comprising triheptanoin, a substrate replacement therapy for patients with fatty acid oxidation disorders, as well as for patients with glucose transporter type-1 deficiency syndrome; and oral formulation of sialic acid to treat hereditary inclusion body myopathy. It has license agreements with AAI Pharma Services Corp. and HIBM Research Group; and a collaboration and license agreement with Nobelpharma Co., Ltd. The company was founded in 2010 and is headquartered in Novato, California.
Is RARE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 90.98
52 Week Low 41.67
Average Volume 483,506
200-Day Moving Average 66.0097
50-Day Moving Average 78.9516
20-Day Moving Average 75.5955
10-Day Moving Average 68.998
Average True Range 3.9148
ADX 36.07
+DI 11.5602
-DI 35.0281
Chandelier Exit (Long, 3 ATRs ) 79.2356
Chandelier Exit (Short, 3 ATRs ) 72.3244
Upper Bollinger Band 92.1626
Lower Bollinger Band 59.0284
Percent B (%b) 0.21
BandWidth 43.830916
MACD Line -4.6998
MACD Signal Line -3.4216
MACD Histogram -1.2781
Fundamentals Value
Market Cap 2.81 Billion
Num Shares 42.6 Million
EPS -6.74
Price-to-Earnings (P/E) Ratio -9.80
Price-to-Sales 16800.34
Price-to-Book 4.53
PEG Ratio -0.21
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 69.13
Resistance 3 (R3) 68.88 67.61 68.62
Resistance 2 (R2) 67.61 66.82 67.73 68.44
Resistance 1 (R1) 66.82 66.33 67.22 67.07 68.27
Pivot Point 65.55 65.55 65.74 65.67 65.55
Support 1 (S1) 64.76 64.76 65.16 65.01 63.81
Support 2 (S2) 63.49 64.27 63.61 63.64
Support 3 (S3) 62.70 63.49 63.47
Support 4 (S4) 62.95